

COPY

RULE 63 (37 CFR § 1.63)
DECLARATION
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled "USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL", the specification of which was filed on March 9, 2000, receiving U.S. Patent Application Serial No. 09/521,738, and further identified as Attorney File No. DI-9.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability in accordance with 37 CFR §§ 1.56(a) and (b) as set forth on the attached sheet indicated Page 3 hereof and which I have read.

I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed
<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>	<u>Yes</u> <u>No</u>

N/A

I hereby claim the benefit under 35 U.S.C. 120 of all United States and PCT international applications listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information material to patentability in accordance with 37 CFR §§ 1.56(a) and (b) which occurred between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
-------------------------------	--------------------	---------------------------------------------

N/A

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

- 1) Inventor's Signature Wayne A. Jensen Date 7/13/00
Inventor's Name (typed): Wayne A. Jensen
Citizenship: United States
Residence: 9133 NCR #5
Wellington, CO 80549
Post Office Address: Same as Residence
- 2) Inventor's Signature Michael R. Lapp Date 7-13-00
Inventor's Name (typed): Michael R. Lappin
Citizenship: United States
Residence: 625 Gait Circle
Fort Collins, CO 80524
Post Office Address: Same as Residence
- 3) Inventor's Signature David K. Rosen Date 7.12.00
Inventor's Name (typed): David K. Rosen
Citizenship: United States
Residence: 7366 Cottage Oak Rd.
Portage, MI 49024
Post Office Address: Same as Residence
- 4) Inventor's Signature Janet S. Andrews Date 7.13.00
Inventor's Name (typed): Janet S. Andrews
Citizenship: United States
Residence: 3308 W. Prospect Rd.
Fort Collins, CO 80526
Post Office Address: Same as Residence

37 CFR §§ 1.56(a) and (b)
DUTY TO DISCLOSE INFORMATION MATERIAL
TO PATENTABILITY

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of a patentability.


A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.*

*Note, 37 CFR §1.97(h) states: "The filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b)."

POWER OF ATTORNEY

On behalf of Heska Corporation, a Delaware Corporation having a principal place of business at 1613 Prospect Parkway, Fort Collins, Colorado 80521, being the assignee of and owning an equal, undivided right, title and interest in the invention entitled "USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL," for which application for Letters Patent of the United States has been made by Wayne A. Jensen, Michael R. Lappin, David K. Rosen, and Janet S. Andrews, said application being identified as Attorney File No. DI-9-1 and executed on even date herewith, I, **Robert B. Grieve**, as **Chairman and CEO** of Heska Corporation, hereby appoint Carol Talkington Verser, Registration No. 37,459; Timothy L. McCutcheon, Registration No. 41,184; Theresa A. Brown, Registration No. 32,547; and Richard J. Stern, Registration No. 50,668; of Heska Corporation, 1613 Prospect Parkway, Fort Collins, Colorado 80525, telephone number (970) 493-7272, as attorneys and agents for Heska Corporation with full powers of substitution, association and revocation to prosecute the application and related U.S. and foreign applications and to transact all business in the United States Patent and Trademark Office and all foreign and international patent offices connected therewith.

Dated: September 25, 2003

By: 
Name: **Robert B. Grieve**
Title: **Chairman and Chief Executive Officer**

POWER OF ATTORNEY

On behalf of Colorado State University Research Foundation, a Colorado non-profit organization having a principal place of business at 601 South Howes, Fort Collins, Colorado 80521, being the assignee of and owning an equal, undivided right, title and interest in the invention entitled "USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL," for which application for Letters Patent of the United States has been made by Wayne A. Jensen, Michael R. Lappin, David K. Rosen and Janet S. Andrews, said application being identified as Attorney File No. DI-9-1 and executed on even date herewith, I, Arundeeep S. Pradhan, as Director of Technology Transfer at Colorado State University Research Foundation, hereby appoint Carol Talkington Verser, Registration No. 37,459; Timothy L. McCutcheon, Registration No. 41,184; Theresa A. Brown, Registration No. 32,547; and Richard J. Stern, Registration No. 50,668; of Heska Corporation, 1613 Prospect Parkway, Fort Collins, Colorado 80525, telephone number (970) 493-7272, as attorneys and agents for Colorado State University Research Foundation with full powers of substitution, association and revocation to prosecute the application and related U.S. and foreign applications and to transact all business in the United States Patent and Trademark Office and all foreign and international patent offices connected therewith.

Dated: Sept. 25. 2003By: Arundeeep S. Pradhan

Name: Arundeeep S. Pradhan

Title: Director of Technology Transfer